Are you Dr. Jackson?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 45 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1550 Orleans St
1m16
Baltimore, MD 21287Phone+1 410-955-7014Fax+1 407-872-0544
Summary
- Dr. Sadhana Jackson, MD is a pediatric hematologist/oncologist in Baltimore, Maryland. She is currently licensed to practice medicine in Maryland and District of Columbia. She is affiliated with Suburban Hospital.
Education & Training
University of TennesseeFellowship, Pediatric Hematology/Oncology, 2010 - 2013
University of Florida (Orlando)Residency, Pediatrics, 2007 - 2010
Eastern Virginia Medical SchoolClass of 2007
Certifications & Licensure
MD State Medical License 2009 - 2026
DC State Medical License 2018 - 2024- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Publications & Presentations
PubMed
- 76 citationsTargeting WNT Signaling for Multifaceted Glioblastoma Therapy.Matthew McCord, Yoh-suke Mukouyama, Mark R. Gilbert, Sadhana Jackson
Frontiers in Cellular Neuroscience. 2017-10-13 - 16 citationsThe MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas.Sadhana Jackson, Eva H. Baker, Andrea M. Gross, Patricia Whitcomb, Andrea Baldwin
Neuro-Oncology Advances. 2020-01-01 - 25 citationsNew Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline Glioma.Davis P. Argersinger, Sarah R. Rivas, Ashish H. Shah, Sadhana Jackson, John D. Heiss
Cancers. 2021-10-21
Press Mentions
- Sylvester Researchers Present Breakthrough Studies at Society for Neuro-Oncology’s Annual MeetingDecember 16th, 2022
- Adding Carboplatin May Help Some Kids with MedulloblastomaJuly 22nd, 2021
Tovorafenib Approved for Some Children with Low-Grade GliomaAugust 8th, 2024
